PKK Library

Your cart is empty.

Welcome to P K Kelkar Library, Online Public Access Catalogue (OPAC)

Advances in Targeted Cancer Therapy (Record no. 502631)

000 -LEADER
fixed length control field 03577nam a22004815i 4500
001 - CONTROL NUMBER
control field 978-3-7643-7414-3
003 - CONTROL NUMBER IDENTIFIER
control field DE-He213
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20161121230709.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 100301s2005 sz | s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9783764374143
-- 978-3-7643-7414-3
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1007/3-7643-7414-4
Source of number or code doi
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RC261-271
072 #7 - SUBJECT CATEGORY CODE
Subject category code MJCL
Source bicssc
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED062000
Source bisacsh
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 614.5999
Edition number 23
245 10 - TITLE STATEMENT
Title Advances in Targeted Cancer Therapy
Medium [electronic resource] /
Statement of responsibility, etc. edited by Paul L. Herrling, Alex Matter, Richard M. Schultz.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture Basel :
Name of producer, publisher, distributor, manufacturer Birkhäuser Basel,
Date of production, publication, distribution, manufacture, or copyright notice 2005.
300 ## - PHYSICAL DESCRIPTION
Extent VII, 303 p.
Other physical details online resource.
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Carrier type code cr
Source rdacarrier
347 ## - DIGITAL FILE CHARACTERISTICS
File type text file
Encoding format PDF
Source rda
490 1# - SERIES STATEMENT
Series statement Progress in Drug Research ;
Volume/sequential designation 63
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Dawn of a new era in molecular cancer therapeutics -- Obtacles and opportunities in the clinical development of targeted therapeutics -- Tumor models for preclinical development of targeted agents -- Angiogenesis inhibitors: What is the clinical future? -- Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy -- Cell survival signaling during apoptosis: Implications in drug resistance and anti-cancer therapeutic development -- Targeted histone deacetylase inhibition for cancer prevention and therapy -- Inhibitors of cyclin-dependent kinase modulators for cancer therapy -- Targeting cyclooxygenase-2 for cancer prevention and treatment -- Antisense approaches in drug discovery and development -- Preclinical development of Alimta™ (Pemetrexed, LY231514), a multitargeted antifolate.
520 ## - SUMMARY, ETC.
Summary, etc. There have been tremendous advances in our understanding of molecular and tumor biology during the past few years. In the field of cancer therapeutics, it is expected that cytotoxic drug approaches will be gradually replaced with treatments based on biological targeted approaches. Hopefully these new targeted therapies will significantly increase efficacy and lack the devastating and troublesome side effects elicited by cytotoxic chemotherapy. This volume is the first book to cover the general topic of targeted cancer therapy. It presents a range of targets such as tumor angiogenesis, cell cycle control and cell signalling, COX-2, apoptosis/cell survival, invasion and metastasis and approaches like kinase inhibitors, antisense, and antibody-based therapeutics. The emphasis is on preclinical development, including target validation, development of biomarkers, strategies for combination approaches, and development of resistance. The particular challenges involved in translating these data to clinical application are discussed. This volume should be of broad general interest to researchers and clinicians involved in cancer therapy as well as other scientists interested in current strategies for cancer treatment.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Medicine.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cancer research.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Molecular biology.
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Biomedicine.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cancer Research.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Molecular Medicine.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Herrling, Paul L.
Relator term editor.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Matter, Alex.
Relator term editor.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Schultz, Richard M.
Relator term editor.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Relationship information Printed edition:
International Standard Book Number 9783764371746
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE
Uniform title Progress in Drug Research ;
Volume/sequential designation 63
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier http://dx.doi.org/10.1007/3-7643-7414-4
912 ## -
-- ZDB-2-SBL
Holdings
Withdrawn status Lost status Damaged status Not for loan Permanent Location Current Location Date acquired Barcode Date last seen Price effective from Koha item type
        PK Kelkar Library, IIT Kanpur PK Kelkar Library, IIT Kanpur 2016-11-21 EBK2918 2016-11-21 2016-11-21 E books

Powered by Koha